Buy Rating for Vertex Pharmaceuticals: FDA Approval of Journavx Boosts Market Potential and Stock Price Target
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...
ETF Daily News7d
Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Cut to $533.00 by Analysts at Piper Sandler
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its target price dropped by Piper Sandler from $535.00 to $533.00 in a report released on Monday,Benzinga reports. The firm currently h ...